Canaccord Genuity Group cut shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning, MarketBeat.com reports. The brokerage currently has $379.00 target price on the pharmaceutical company’s stock, up from their prior target price of $332.00. VRTX has been […]